Trieste, December 9th 2024 – The microbiome market is on the cusp of a major breakthrough, with groundbreaking research and increasing consumer awareness driving unprecedented growth. As scientists unravel the intricate relationship between the human microbiome and overall health, the market for microbiome-based products and services is poised to reach new heights.
As a context, the global gut microbiome market is expected to record a CAGR of 17.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 717.2 Million. By 2033, the valuation is anticipated to reach USD 2,969.4 Million (source).
The microbiome, consisting of trillions of microorganisms that live in and on our bodies, plays a critical role in various bodily functions, including digestion, immunity, and mental health. Recent advancements in microbiome research have revealed the potential of targeting the microbiome to prevent and treat a wide range of diseases, from digestive disorders to autoimmune conditions.
Key factors driving the growth of the microbiome market include:
- Growing consumer interest in gut health: Consumers are increasingly seeking natural and holistic approaches to health, leading to a surge in demand for probiotics, prebiotics, and other microbiome-supporting products.
- Advancements in microbiome research: Ongoing research is uncovering new insights into the microbiome-gut-brain axis, microbiome-immune interactions, and the role of the microbiome in chronic diseases.
- Development of personalized microbiome therapies: Tailored microbiome-based treatments are emerging, offering the potential for more effective and personalized healthcare.
- Increased investment in microbiome companies: Venture capital firms and pharmaceutical companies are investing heavily in microbiome startups, fueling innovation and accelerating the development of new products and services.
Ulisse Biomed Group is strategically positioning to be an emerging leader in the microbiome industry. With specific focus in microbiome testing and diagnostics Ulisse Biomed Group and Hyris are leveraging its existing platform of hardware, software and medical consumables alongside its technological capabilities to bring new targeted and cost effective tests to this innovative and evolving field of human diagnostics.
Bringing best in class quality control alongside technologically leading diagnostics a partnership with Gutsy was created, a North American-based organization that is active in microbiome testing. Gutsy who are a leader in qPCR applications for microbiome chose Ulisse Biomed and its proprietary Hyris System™ for targeted development and scale deployment for direct to consumer testing which start with metabolic syndrome and will grow to more targeted microbiome testing. Gutsy are ecstatic with the early results and in collaboration with Ulisse Biomed targeted programs already underway and will be launched within the next year.
“We strongly believe in this application area, which still have to unleash its real impact” says Lorenzo Colombo, CTO at Ulisse Biomed. “We approached gut microbiome testing at first, but we are already targeting other application areas, for example in women health and vaginal microbiome, considering there are evident synergies and complementarities with our current main focus, that is papilloma virus and STDs testing”.
“We are committed and ready to embrace new opportunities in this field”, adds Gabriele Salaris, Head of Marketing & Sales at Ulisse Biomed. “This application area is expected to be a significant growth driver for the group's revenues in the next years”, concludes Salaris.